Tüdőrák: nyitott vizsgálatok itt: Norvégia
23 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 2026. nov. 10.. Ask the study team whether a trial fits you.
3. fázisToborozTrial-stage medicine
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
- Where
- Bergen, Drammen, Gjoevik, Loerenskog, Oslo, Stavanger, Trondheim
- Age
- 18 év and over
- People
- 1264 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT06119581EU 2023-503412-33-00Regiszter frissítve: 2026-11-04
3. fázisToborozTrial-stage medicine
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
- Where
- Arendal, Bergen, Drammen, Gjøvik, Oslo
- Age
- 18 év and over
- People
- 700 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT06890598EU 2024-512302-25-00Regiszter frissítve: 2026-11-04
2. fázisToborozTrial-stage medicine
A Study of Navlimetostat (BMS-986504) Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)
- Where
- Bergen, Oslo
- Age
- 18 év and over
- People
- 254 worldwide
- Run by
- Bristol-Myers Squibb
See details and how to joinNCT07492680Regiszter frissítve: 2026-11-04
2/3. fázisToborozTrial-stage medicine
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
- Where
- Drammen
- Age
- 18 év and over
- People
- 626 worldwide
- Run by
- Mirati Therapeutics Inc.
See details and how to joinNCT04613596EU 2023-508922-83-00Regiszter frissítve: 2026-10-30
3. fázisToborozTrial-stage medicine
DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemoimmunotherapy
- Where
- Bergen, Oslo, Trondheim
- Age
- 18 év and over
- People
- 670 worldwide
- Run by
- Boehringer Ingelheim
See details and how to joinNCT07472517EU 2025-520565-51-00Regiszter frissítve: 2026-10-28
No phaseToborzás még nem indultResearch participation
New Smoking Cessation Intervention in Primary Care - a Randomized Controlled Trial
- Where
- Levanger
- Age
- 18 év and over
- People
- 620
- Run by
- Helse Nord-Trøndelag HF
See details and how to joinNCT07900724Regiszter frissítve: 2026-10-28
2. fázisToborozTrial-stage medicine
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
- Where
- Lørenskog, Oslo
- Age
- 18 év and over
- People
- 740 worldwide
- Run by
- Daiichi Sankyo
See details and how to joinNCT06172478EU 2023-507641-29-00Regiszter frissítve: 2026-10-26
2/3. fázisToborozTrial-stage medicine
A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion
- Where
- Oslo
- Age
- 18 év and over
- People
- 590 worldwide
- Run by
- Bristol-Myers Squibb
See details and how to joinNCT07063745EU 2025-521511-40-00Regiszter frissítve: 2026-10-23
3. fázisToborozTrial-stage medicine
A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)
- Where
- Drammen, Graalum
- Age
- 18 év and over
- People
- 750 worldwide
- Run by
- Bristol-Myers Squibb
See details and how to joinNCT07361510EU 2025-523586-18-00Regiszter frissítve: 2026-10-23
3. fázisToborozTrial-stage medicine
Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer
- Where
- Bergen, Drammen, Oslo
- Age
- 18 év and over
- People
- 695 worldwide
- Run by
- Gilead Sciences
See details and how to joinNCT06801834Regiszter frissítve: 2026-10-20
No phaseToborozResearch participation
Optimizing Patient Treatment With EPA-enriched Nutrition, a Randomised Control Trial
- Where
- Oslo
- Age
- 18 év and over
- People
- 118 worldwide
- Run by
- University of Edinburgh
See details and how to joinNCT07255066Regiszter frissítve: 2026-10-20
3. fázisToborozResearch participation
A Study to Test How Well ZL-1310 may Work Compared to Therapies Selected by the Investigator in Treating Patients with Relapsed Small Cell Lung Cancer
- Where
- Drammen, Gjoevik, Oslo
- Age
- 18 év and over
- People
- 263 worldwide
- Run by
- Zai Lab (US) LLC
See details and how to join2025-522818-23-00EU 2025-522818-23-00Regiszter frissítve: 2026-10-19
3. fázisToborozTrial-stage medicine
A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
- Where
- Brumunddal, Drammen, Loerenskog, Oslo
- Age
- 18 év and over
- People
- 780 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06312137EU 2023-508012-35-00Regiszter frissítve: 2026-10-15
2/3. fázisToborzás még nem indultResearch participation
IZABRIGHT-Lung01: Study of Izalontamab Brengitecan (BMS-986507) versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer after failure of EGFR TKI Therapy
- Where
- Bergen, Drammen, Oslo
- Age
- 18 év and over
- People
- 173 worldwide
- Run by
- Bristol-Myers Squibb Services Unlimited Company
See details and how to join2025-521908-22-00EU 2025-521908-22-00Regiszter frissítve: 2026-10-13
2/3. fázisToborozTrial-stage medicine
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
- Where
- Bergen, Drammen, Oslo
- Age
- 18 év and over
- People
- 500 worldwide
- Run by
- Bristol-Myers Squibb
See details and how to joinNCT07100080Regiszter frissítve: 2026-10-09
No phaseToborozResearch participation
Augmented Endobronchial Ultrasound (EBUS-TBNA) With Artificial Intelligence
- Where
- Levanger, Trondheim
- Age
- 18 év and over
- People
- 50
- Run by
- Norwegian University of Science and Technology
See details and how to joinNCT05739331Regiszter frissítve: 2026-09-30
2. fázisToborzás még nem indultResearch participation
A phase II randomised trial investigating the benefit of adjuvant immunotherapy after neoadjuvant chemoimmunotherapy for resectable NSCLC (ADIL)
- Where
- Bergen, Lorenskog, Oslo, Tromsoe, Trondheim
- Age
- 18 év and over
- People
- 300 worldwide
- Run by
- Oslo Universitetssykehus HF
See details and how to join2025-524439-38-00EU 2025-524439-38-00Regiszter frissítve: 2026-09-28
No phaseToborozResearch participation
Lung cAncer Robotic Comparative Study
- Where
- Loerenskog
- Age
- 18 év and over
- People
- 600 worldwide
- Run by
- Intuitive Surgical
See details and how to joinNCT06038227Regiszter frissítve: 2026-09-14
3. fázisToborozResearch participation
Study of Sacituzumab Govitecan Versus Standard of Care in Participants with Previously Treated Extensive Stage Small Cell Lung Cancer
- Where
- Bergen, Drammen, Oslo
- Age
- 18 év and over
- People
- 355 worldwide
- Run by
- Gilead Sciences Inc.
See details and how to join2024-515884-69-00EU 2024-515884-69-00Regiszter frissítve: 2026-08-31
3. fázisToborzás még nem indultResearch participation
Does a higher radiation dose prolong survival of patients with limited-stage small cell lung cancer receiving immunotherapy after chemotherapy and radiation therapy (DAHRTS trial)?
- Where
- Aalesund, Bergen, Bodo, Drammen, Haugesund, Kristiansand S, Levanger, Lorenskog, Oslo, Stavanger, Tromsoe, Trondheim
- Age
- 18 év and over
- People
- 426 worldwide
- Run by
- Norges Teknisk-Naturvitenskapelige Universitet NTNU
See details and how to join2026-525513-31-00EU 2026-525513-31-00Regiszter frissítve: 2026-08-24
No phaseToborozResearch participation
Akershus Cardiac Examination (ACE) 5 Study
- Where
- Lørenskog
- Age
- 60 év to 79 év
- People
- 1000
- Run by
- University Hospital, Akershus
See details and how to joinNCT07301489Regiszter frissítve: 2025-12-24
1/2. fázisToborozResearch participation
COMBINATORY IMMUNOTHERAPY-2 (COM-IT-2) A phase 2 randomised open two-arm study to assess the tolerability and efficacy of immunotherapy combined with extensive radiotherapyfor the treatment of stage IV non-small cell lung cancer
- Where
- Gjoevik, Oslo, Trondheim
- Age
- 18 év and over
- People
- 55
- Run by
- Oslo University Hospital HF
See details and how to join2023-510089-28-00EU 2023-510089-28-00Regiszter frissítve: 2025-06-20
2. fázisToborozTrial-stage medicine
Efficacy and Safety of Anti-PD-1/PD-L1 Treatment +/- UV1 Vaccination in Patients With Non-small Cell Lung Cancer
- Where
- Brumunddal, Drammen, Foerde, Levanger, Loerenskog, Oslo, Stavanger, Tromsoe, Trondheim
- Age
- 18 év and over
- People
- 138
- Run by
- Vestre Viken Hospital Trust
See details and how to joinNCT05344209EU 2022-502437-25-00Regiszter frissítve: 2023-11-09
Minden vizsgálat (Tüdőrák) és a térkép
Ez az oldal nem orvosi tanács. Mielőtt egy vizsgálatot megkeresel, beszélj az orvosoddal.